Archivel Farma is a biotech company focused on the development of innovative immunotherapeutic products.

Our facilities are engineered to manufacture small-customized clinical batches under GMPs.

RUTI® vaccine, our own project for fighting against Tuberculosis.

Mission & Values

Our mission is to guide you and your product from early stages of development to the first clinical phases.


We are committed to new approaches, capable of providing real solutions to develop of innovative drug products.


Archivel Farma is an organization that learns from experience and constantly adapts to a changing and challenging environment.


A team with the highest professional standards guarantees the quality of our services and the rigor of the results.


Our facilities are carefully engineered and uniquely built to support and enable early phase development for injectables and freeze dried products.


We are committed to take your product forwards to early clinical stages, providing agile and flexible and customized services.

Leadership team

Ever-growing team of highly qualified pharmacy, biology and biopharmaceutical experts to find smart solutions to the challenging area of innovate drug development.



Mercè Amat
Head of Research & Development
Leader of RUTI project


Mercè Amat has a PhD in Biochemistry from the University of Barcelona. She has broad professional experience in the sectors of bioscience and pharmaceuticals. For more than nine years, she led biological projects in respiratory and arthritis areas in the Research Departments at Almirall and at Menarini before joining Archivel Farma as Head of R&D in 2008. Currently, the focus of her work is on the development of RUTI®, most notably in the improvement of the manufacturing process and the product characterization. She is also conducting research on the use of RUTI® beyond tuberculosis.

Joan Casanovas
Head of the Production
Leader of Services


Joan Casanovas holds a Bachelor’s degree in Biology by the University of Barcelona. In recent years he has developed his professional career in London, working in the Cellular Therapy department at Great Ormond Street Hospital  and Gene Therapy at University College London (UCL). He was involved in the translation of Lymphocyte manufacture for immunotherapy clinical trials, from research to GMP standards. Joan joined Archivel’s team in October 2019 as Production Manager, with the goal of manufacturing RUTI® vaccine.

Janina Duch
Quality Control Manager


Janina Duch is a Technician in Analysis and Quality Control from the IES Narcís Monturiol in Barcelona. With a professional trajectory of more than 10 years of experience working in the pharmaceutical industry, and numerous specific training courses around Quality, she has worked in companies as Sandoz and Biofarm Biotechnology.

Marc Jordan
Technical Director and Quality Assurance Manager


Marc is a graduate in Pharmacy by the University of Barcelona and has a Master’s degree in pharmaceutical industry (CESIF). He started his professional career in Fleming S.A, dedicated to Medical Devices. Afterwards, he incorporated into the Audit and Quality Systems Department at Grifols S.A.; where he was able to work with Biological Medicines. In 2017, he joined Archivel Farma S.L. as a Quality Assurance Technician and, at this moment, occupies the charge of Head of Quality Assurance and Qualified Person.


Private Funding

Archivel Farma is a private company, founded in 2005, which has as main investors TGT Group and Archivel Technologies, and has a minority participation of Laboratorios Reig Jofré.


In its different stages of development, the company has received financial support from investment funds such as FonsInnocat (BcnHighGrowth); Agora Invest; Inversions Valor Afegit; and Etios Capital Invest. All of them exited Archivel Farma in 2011.

Public Funding

The company has also received public funds from CDTI (Center for the Development of Industrial Technology); ENISA (Empresa Nacional de Innovación, SA); the missing Genoma España Foundation, now FECYT; and ACCIÓ, Catalan Agency for Business Competitiveness, as well as European funds through H2020 Research and Innovation projects.



Archivel Farma co-develop Advanced therapy medicinal products (ATMPs) in a partnership with Reig Jofre Lab


Archivel Farma collaborates with COMSER Pharma in the development of freeze dried biological products as the manufacturer of clinical batches.

Archivel on the media

TV3, QuèQuiCom –2016

TV3, Trenta Minuts –2011



Archivel Farma launches its new website on the World TB Day 2018

Archivel Farma has decide to launch its new website to coincide with the World TB…
Read More
Press release

Archivel Farma and Laboratorios Silanes to collaborate in the development of the anti-tuberculosis vaccine RUTI® in México

RUTI® is the most promising therapeutic vaccine among the dozen projects that are currently being…
Read More

Archivel Farma participated in the TBVI Symposium on therapeutic vaccination

Dr Pere-Joan Cardona, inventor of RUTI® vaccine and Scientific Advisor of Archivel Farma, and Olga…
Read More
Press releaseResearch

The RUTI® vaccine for the treatment of tuberculosis, presented to the WHO experts

Archivel Farma, owner of the vaccine, has started a Phase IIa clinical trial to assess…
Read More

Archivel supports the 2017 World TB Day event in Barcelona

Archivel Farma is supporting a year more the activities organized in Barcelona around the World…
Read More

TGT Group extends its participation in the capital of Archivel Farma

TGT Group, a strategic partner of Archivel Farma since January 2012, has increased its participation…
Read More

Dr. Pere-Joan Cardona writes on TB therapeutic vaccines in ‘Frontiers in Microbiology’

The peer-reviewed journal Frontiers in Microbiology has just published an article by Dr. Pere-Joan Cardona, scientific advisor of…
Read More
Press release

Archivel Farma looks for partners to start the last stage of development of RUTI® vaccine

Archivel has carried out a restructuring of its equipment to facilitate the entry of new…
Read More

Results of RUTI®‘s Phase II clinical trial, published in Plos One

The prestigious magazine Plos One has just published the article "Safety, Tolerability, and Immunogenicity of…
Read More
Press release

Archivel secures funding to bring the anti-tuberculosis therapeutic vaccine RUTI® to market

TGT, an industrial group from Barcelona, Spain, has facilitated the exit of the financial investor…
Read More